MicroRNA‑127‑5p attenuates severe pneumonia via tumor necrosis factor receptor‑associated factor 1
Cunrong Chen, Sen Lin, Lili Zhou, Jingjing Wang, Junnian Chen, Ranjie Yu, Haoteng Luo, Junli Lu, Zhiqiang Xue, Mingzhi Chen
Abstract
Pneumonia is a persistent and pervasive disease, the effects of which can be severe. MicroRNA (miR)‑127‑5p has been utilized as a novel biomarker for the diagnosis of severe pneumonia. The present study aimed to investigate the function of miR‑127‑5p during severe pneumonia. An in vitro model of severe pneumonia in Ana‑1 murine macrophages was established using lipopolysaccharide (LPS). Subsequently, reverse transcription‑quantitative PCR and ELISA were performed to detect the mRNA and protein expression levels of interleukin (IL)‑1β, IL‑6 and tumor necrosis factor (TNF)‑α. Western blotting was also performed to measure the activity of AKT and NF‑κB. The results indicated that compared with the control group, LPS treatment increased TNF receptor‑associated factor 1 (TRAF1) expression levels and reduced miR‑127‑5p expression levels. Furthermore, the results revealed that the 3'‑untranslated region of TRAF1 was targeted by miR‑127‑5p. miR‑127‑5p mimic reduced LPS‑induced increases in IL‑1β, IL‑6 and TNF‑α expression by targeting TRAF1, which was potentially mediated by inactivation of the AKT and NF‑κB signaling pathways. Collectively, the results demonstrated that miR‑127‑5p may attenuate severe pneumonia by reducing LPS‑induced inflammatory cytokine production, and inactivating the AKT and NF‑κB signaling pathways by targeting TRAF1.